We describe the design and synthesis of nonpeptidal antagonists of the peptide hormone cholecystokinin. Several of these compounds have high specificity and nanomolar binding affinity and are active after oral administration. To our knowledge, the design of such agents has not previously been accomplished for any peptide hormone. The structural similarities between these synthetic compounds and the anxiolytic 1,4-benzodiazepines are noted, and the potential of this structural feature for future design of ligands for other peptide hormone receptors is discussed.
. However, asperlicin has liabilities as a pharmacological or potential therapeutic agent, including lack of oral bioavailability, modest potency, and poor water solubility (7, 42) .
Many important drugs such as ivermectin (18) and cefoxitin (19) are semisynthetic derivatives of natural products, suggesting that derivatization of asperlicin might generate imLong-acting orally effective agents that interact competitively at peptide receptors are essential for the optimal development of important discoveries in the neuropeptide field. Such compounds represent unique biological reagents for determining unambiguously the role ofthe parent neurotransmitter or neurohormone in normal physiology and for assessing its contribution to pathophysiology. They are also of considerable importance in their own right as potential therapeutic agents.
Advances have been made in the design of metabolically stable peptide analogs (1) , but the problem of achieving good oral bioavailability with such compounds remains unsolved. Nonpeptidal analogs could offer a broader range of possible solutions to this problem. Unfortunately, the design of biologically equivalent nonpeptidal analogs of bioactive peptides has not yet been achieved (2) . The only previously known examples of effective nonpeptidal ligands for peptide hormone receptors are the enkephalin agonist, morphine (2, 3) , and the recently reported cholecystokinin (CCK) antagonist, asperlicin (4) (5) (6) (7) . Both are complex natural products having poor oral bioavailability. In this paper, we describe the design and synthesis of 3-substituted-1,4-benzodiazepines, which are selective high-affinity antagonists of CCK, having good oral activity of long duration.
CCK [active core (CCK-8), H-Asp-Tyr(SO3H)-Met-GlyTrp-Met-Asp-Phe-NH2 (8) ] is a gastrointestinal peptide hormone implicated in the control of pancreatic and biliary secretion, gall bladder contraction, and gut motility (9) (10) (11) (12) . Recent studies have suggested a key role for CCK in the central nervous system as well, perhaps as a neurotransmitter or neurohormone (11) (12) (13) (14) (15) . Until (22), and this observation provided a rationale for one possible approach to elaboration ofthe basic ring 2-i.e., fusion with L-tryptophan (3).
Examination of Scheme I reveals that asperlicin is not a particularly close analog of the ring system exemplified by 2. Specifically, the 5-phenyl substituent in 2 is absent in 1, which contains instead a quinazoline ring fused to the opposite (1, 2) side of the seven-membered ring. For modeling purposes, these two substituents can be approximately superimposed by rotation of 1 1800 about the horizontal in-plane axis as shown in Scheme II. However, as illustrated, Table  2 . Table 2 (compounds 6, 8, 9, and 10) were prepared by base-mediated cyclization of a-aminoamides using published methods (25) . The a-aminoamides were obtained either by acylation ofthe appropriate 2-aminobenzophenone with D-or L-tryptophan acid chloride, or by coupling with BOC-D-or -L-tryptophan followed by acid-catalyzed N-deprotection. 3-Amidobenzodiazepines (compounds 14-16, 18, 19, and 21) were obtained by acylation of the 3-amino derivatives. The latter were prepared from the 3-hydroxy compounds using published procedures (26) (27) (28) (24) .
MATERIALS AND METHODS Compound 5 and the other 3-alkylbenzodiazepines shown in
of the corresponding ethyl esters. The triazole ring (compound 12) was fused to 9 using published procedures (29 18 . These studies are described in the accompanying paper (24) .
RESULTS AND DISCUSSION
The critical structure in our new approach to the synthesis of effective antagonists of CCK was the prototype, compound 5. Biological evaluation of this compound demonstrated the validity of our approach. Although much simplified, compound 5 proved nearly as potent a ligand for pancreatic CCK receptors as 1 ( Table 2) . Equally important, 5, unlike 1, was well-absorbed after oral administration and was found to be an orally effective antagonist of CCK (V. J. Lotti and R. S. L. Chang, personal communication). Consistent with our rationale, compound 5 was nearly 10-fold more potent than the known 3S enantiomer 6 (Table 2) , which had been reported earlier (32) to be a weak anti-anxiety agent. This low anxiolytic activity is not unexpected in view of the known deleterious effect of most 3-alkyl substituents on anti-anxiety activity in the benzodiazepine series (33, 34) , and it is a desirable feature in our compounds, given our analog design objectives.
The success of compound 5 prompted us to undertake extensive structure/activity studies, the key findings from which may be illustrated by using the selected analogs listed in Table 2 . These studies showed the CCK antagonist potencies of compounds derived from 5 to be highly sensitive to the nature of the group attached to the 3-position of the benzodiazepine ring and to the linkage forming the attachment (see Table 2 ). The 3-amidobenzodiazepine group (e.g., [14] [15] [16] [17] [18] [19] [20] [21] [22] in particular provided a series of superior CCK antagonists, exemplified by the (3S)-2-indole amide 18 (L-364,718), the most potent competitive antagonist of CCK yet described (24) . This compound is 3 orders of magnitude more potent than the lead structures 1 and 5, at least 80-fold more potent than its own 3R enantiomer 19, and some 6 orders of magnitude more potent than the much studied CCK antagonist, proglumide (Table 1) . Its affinity for the CCK receptor is comparable to that of . Compound 18 is selective for pancreatic CCK receptors versus brain CCK and gastric gland gastrin receptors, and is orally effective as an antagonist of CCK-8-induced gastric emptying (24) . A detailed account of the biochemical and pharmacological properties of compound 18 is given in the accompanying paper (24) .
Amide 18 is one of a class of potent CCK antagonists that allows a clearer examination of the relationship between the CCK antagonist and anti-anxiety activities of benzodiazepines. This relationship is an important one, since recent reports (35) (36) (37) (38) have suggested a CCK antagonist activity for anti-anxiety benzodiazepines themselves (i.e., diazepam; 2). The data in Table 2 illustrate how substitution in the benzodiazepine ring affects CCK receptor binding potencies as compared with its influence on reported anti-anxiety activities. Thus, some substitutions such as 2'-fluoro (Y = F), N1-methyl (R1 = CH3), and N1-C2-triazole fusion [ZR1 = =N-N=C(CH3)-] have effects on CCK receptor affinity similar to those reported in the anti-anxiety series (33, 39) : they provide potent compounds in each case. N1-carboxymethyl (R, = CH2COOH), on the other hand, greatly reduces anti-anxiety potency (34) , but gives potent CCK receptor ligands (13 and 20) . Conversely, 7-substituents such as chloro (X = Cl) are, if anything, slightly detrimental to CCK receptor affinity but are vital for good anti-anxiety activity (33) .
Most importantly in the present case, of course, are the effects of 3-substitution. 3-Alkyl and 3-amido substituents are reported (23, (32) (33) (34) 40) to be detrimental to anti-anxiety activity. Our results are consistent with these reports. Thus, as shown by the data in Table 2 , our 3-alkyl and 3-amido substituents greatly enhance CCK antagonist potency but greatly diminish the anti-anxiety-related benzodiazepine receptor binding activity: selectivity changes from >104 in favor of benzodiazepine vs. CCK receptors to >104 in favor of CCK (>108-fold reversal) in the conversion of 2 to 18. Furthermore, the stereochemical preference for anti-anxiety activity in the 3-alkyl enantiomers 5/6 is the same as that reported for 3-methylbenzodiazepines (3S) (32, 40) , and it is opposite to that preferred for CCK antagonist potency (3R) ( It should be noted that for all the CCK antagonists reported here, the preferred orientation of the 3-substituent in space is the same. The apparent change in preferred stereochemistry from R to S between the alkyl (e.g., 5/6) and amide (e.g., 18/19) series is an artifact of the convention used to assign the stereochemical designator (41) .
In retrospect, the development of the lead structure 5 to the much more effective 18 eclipsed the rationale by which the indole methyl side chain was chosen for compound 5-namely, its resemblance to the side chain of L-tryptophan. More importantly, however, the outstanding success of 18 strengthened the central hypothesis of this work-that the 5-phenyl-1,4-benzodiazepine ring exemplified by 2, 5, and, especially, 18, can provide a useful base for the design of peptide receptor ligands.
CONCLUSION
In summary, we report here the conception and development of the first specific nonpeptidal antagonist of CCK with nanomolar potency and good oral bioavailability. To the best of our knowledge, this is the first example of such a ligand deliberately designed for any peptide receptor. Studies of this compound 18, and its analogs have already provided evidence for the distinction between CCK and benzodiazepine receptor binding activities of benzodiazepines and may add as well to the understanding of the mechanism of binding of anti-anxiety agents such as 2 to their receptors.
Whether the benzodiazepine ring in 2 and 18 serves as a conventional structural mimic for key portions of the respective natural ligands or whether it exploits some as yet unidentified feature common to peptide receptors remains unclear. What is clear is that this ring system has now provided very effective ligands for two different peptide receptors, suggesting a generality that could be of much use in the design of ligands for still other such receptors.
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